Tomivosertib (eFT-508)

Catalog No.S8275 Batch:S827501

Print

Technical Data

Formula

C17H20N6O2
Molecular Weight 340.38 CAS No. 1849590-01-7
Solubility (25°C)* In vitro DMSO 13 mg/mL (38.19 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.65mg/ml Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.312mg/ml Taking the 1 mL working solution as an example, add 50 μL of 6.25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Targets
MNK2 [1]
(Cell-free assay)		 MNK1 [1]
(Cell-free assay)
1 nM 2.4 nM
In vitro

eFT508 has a half-maximal inhibitory concentration (IC50) of 1-2 nM against both MNK isoforms in enzyme assays and inhibits the kinase through a reversible, ATP-competitive mechanism of action. Treatment of tumor cell lines with eFT508 leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50 = 2-16 nM). In a panel of ~50 hematological cancers, eFT508 shows anti-proliferative activity against multiple DLBCL cell lines. Sensitivity to eFT508 in TMD8, OCI-Ly3 and HBL1 DLBCL cell lines is associated with dose-dependent decreases in production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10[1].
In vivo

eFT508 is well-tolerated and shows efficacy against MyD88-mutant DLBCL models in vivo. Significant anti-tumor activity of eFT508 is observed in the TMD8 and HBL-1 ABC-DLBCL models(subcutaneous human lymphoma xenograft models), both of which harbor activating MyD88 mutations[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    TMD8 cells

  • Concentrations

    0.01, 0.1, 1, 3, 10 μM

  • Incubation Time

    24 h

  • Method

    TMD8 cells are treated with the indicated concentrations of eFT508 for 24 h. Cell lysates are subjected to m7-GTP Sepharose pull-down and bound proteins are analyzed by immunoblotting with the indicated antibodies.

Selleck's Tomivosertib (eFT-508) has been cited by 11 publications

Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy [ PLoS Biol, 2023, 21(8):e3002227] PubMed: 37531320
MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma [ Hum Exp Toxicol, 2023, 42:9603271231158047] PubMed: 36840478
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers [ JCI Insight, 2022, 7(22e158060)] PubMed: 36256477
Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment [ J Transl Med, 2022, 20(1):276] PubMed: 35717238
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor [ J Med Chem, 2022, 10.1021/acs.jmedchem.1c01941] PubMed: 35417652
Inhibition MNK-eIF4E-β-catenin preferentially sensitizes gastric cancer to chemotherapy [ Fundam Clin Pharmacol, 2022, 10.1111/fcp.12759] PubMed: 35048413
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses [ J Clin Invest, 2021, 140752] PubMed: 33690225
Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer [ Cell Rep Med, 2020, 1(8):100131] PubMed: 33294856
eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis [ Elife, 2020, 9e60151] PubMed: 33135632
Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor. [ Biomolecules, 2019, 10(1)] PubMed: 31878201

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.